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Abstract
Background: Incidence rates of travellers’ diarrhoea (TD) need to be updated and risk factors are insufficiently
known.
Methods: Between July 2006 and January 2008 adult customers of our Centre for Travel Health travelling to a
resource-limited country for the duration of 1 to 8 weeks were invited to participate in a prospective cohort study.
They received one questionnaire pre-travel and a second one immediately post-travel. First two-week incidence
rates were calculated for TD episodes and a risk assessment was made including demographic and travel-related
variables, medical history and behavioural factors.
Results: Among the 3100 persons recruited, 2800 could be investigated, resulting in a participation rate of 89.2%.
The first two-weeks incidence for classic TD was 26.2% (95%CI 24.5-27.8). The highest rates were found for Central
Africa (29.6%, 95% CI 12.4-46.8), the Indian subcontinent (26.3%, 95%CI 2.3-30.2) and West Africa (21.5%, 95%CI
14.9-28.1). Median TD duration was 2 days (range 1-90). The majority treated TD with loperamide (57.6%), while a
small proportion used probiotics (23.0%) and antibiotics (6.8%). Multiple logistic regression analysis on any TD to
determine risk factors showed that a resolved diarrhoeal episode experienced in the 4 months pre-travel (OR 2.03,
95%CI 1.59-2.54), antidepressive comedication (OR 2.11, 95%CI 1.17-3.80), allergic asthma (OR 1.67, 95%CI 1.10-2.54),
and reporting TD-independent fever (OR 6.56, 95%CI 3.06-14.04) were the most prominent risk factors of TD.
Conclusions: TD remains a frequent travel disease, but there is a decreasing trend in the incidence rate. Patients
with a history of allergic asthma, pre-travel diarrhoea, or of TD-independent fever were more likely to develop TD
while abroad.
Background
Travellers’ d i a r r h o e a( T D ) ,t h em o s tc o m m o nh e a l t h
problem in visitors to tropical and subtropical destina-
tions, affects between 20 to over 60% of persons during
a two weeks stay in a high risk country such as India or
Kenya [1-3]. As many of those data have been generated
some decades ago, the aim of this study is to provide
updated region-based TD incidence rates, and to investi-
gate risk factors.
Methods
Study design
Based on a protocol approved by the Ethical Commis-
sion of the Canton of Zurich, we performed a prospec-
tive questionnaire-based cohort study.
Study population
Potential participants were recruited at the Centre for
Travel Health of the University of Zurich between July
2006 and January 2008. To be included, participants had
to be adult, German-speaking Swiss residents who
planned to travel to high-risk TD destinations [2,4] for a
duration of 1 to 8 weeks. Subjects planning to take pro-
phylactic antibiotics during their trip, those who
reported a history of severe illness (anaemia, cancer,
immunodeficiency or immunosuppressive disorders,
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any medium, provided the original work is properly cited.severe psychiatric illness, previous gastrointestinal sur-
gery), with functional organic gastrointestinal disorders
(according to Rome II [5]/Rome III [6] criteria), or
recurring diarrhoeal symptoms within a four months
pre-travel period, and pregnant women were excluded.
Definitions
Classic TD was defined as three or more unformed stools
per 24 h with at least one accompanying symptom (nau-
sea, vomiting, abdominal cramps, tenesmus, fever, blood
in stools)[7,8], while 3 or more unformed stools with or
without additional symptom(s) was named TD based on
the UNICEF/WHO definition [9,10]. Patients experien-
cing one or two loose stools per 24 h while abroad were
classified as having mild diarrhoea [8,10]. TD and classic
TD were used for incidence calculations in the first two
weeks of stay abroad and only TD for multiple logistic
regression analysis. TD patients, who reported fever or
blood in their stools were rated as having dysentery. Mul-
tiple episodes of TD had to be separated by a TD-free
interval of at least 72 hours. Incapacitation meant an
inability to pursue planned travel activities and was rated
in 3 subgroups; low incapacitation could pursue all activ-
ities, and severe was defined by being confined to bed for
at least 12 hours or by consulting a doctor [4,7]. Body
Mass Index (BMI) was calculated from participants’
height and weight data at enrolment. Origin was the
country in which the participant spent the first five years
of life. ‘Newcomers’ were visiting the index travel region
for the first time. Countries and subcontinents were
grouped according to the United Nations World Migrant
Stock [11]. Comedication and diseases were classified
according to the main categories of the International
Classification of Diseases (ICD-10 2007)[12]. Allergies
formed a separate disease entity including allergic
asthma, allergic rhinitis, hymenoptera and atopic derma-
titis, those were self-reported by the study participant,
but an MD confirmation or diagnosis was requested.
Study conduct
Participants who visited our Centre for Travel Health
for standard pre-travel consultation were invited to par-
ticipate in the study on a voluntary basis. Pre-travel
advice regarding TD included an explanation of TD
etiology, mode of pathogen transmission, preventive
behaviour, treatment options and, if indicated, written
instructions on how to use antibiotics. A leaflet on gen-
eral medications (including such against TD) was pro-
vided as part of a travel medical kit. Upon signing an
informed consent, the participants received two ques-
tionnaires. Q1 was collected immediately upon comple-
tion, while Q2 was to be returned in the first week after
their return reminded either by mail or email; Q2 was
similar to a diary.
Q1 included 30-structured questions to assess the itiner-
ary, previous travel to the tropics, demographic data, body
mass index, chronic diseases, confirmed allergies, and pre-
travel diarrhoea characteristics. In addition, adverse life
events in the preceding 12 months, self-reported stress,
smoking habits and alcohol consumption, and perceived
susceptibility to diarrhoea were investigated.
Q2 consisted of 17-questions to confirm the travel
itinerary and to document a detailed history of TD
abroad, including TD medication used. After an initial
trial phase of three months we added questions about
syndromes abroad (health impairments reported abroad,
i.e. TD independent fever) and attitudes towards diar-
rhoea (catering, adherence to ‘cook it, boil it, peel it or
forget it’, tap water consumption) [13,14]. Non-
responders were reminded by mail twice; patients
reporting uncured diarrhoea were followed until
resolution. Those who refused to respond to Q2 were
interviewed with the single question whether they had
experienced diarrhoea while abroad. No stool samples
were collected in this study.
Statistical analysis
Data were analysed using Stata statistical software, ver-
sion 10.1 (Stata).
The 95% confidence intervals (CI) for the incidence
rates in various subcontinents were estimated as per
Newcombes’ exact (not approximative) method [15]. We
compared differences in proportions of demographics,
attitudes and clinical variables using the chi square tests.
The significance level was set at a (alpha) = 0.05. All tra-
vel- and traveller-related risk factors were evaluated as
independent potential risk factors for the development of
TD in a multiple logistic regression model. Odds ratios
(OR) were determined by stepwise backward elimination
of variables with p > 0.100. For the multiple logistic
regression analysis only, the later inserted question refer-
ring to TD-independent fever was analysed by imputing
with organising the missing data using the pattern of
gender, destination continent and education. Single
imputation by regression imputes for cases with missing
values on a variable instead of mean values of this vari-
able function values for this variable out of a regression
equation with the following independent variables: edu-
cation, gender and destination. For the sensitivity tests,
the results of the multiple analysis of the complete data-
set were compared first to a selection of half of the data
and second, to the classic TD definition.
Results
Demographics
Among 3100 enrolled travellers, 2800 (90.3%) were eligi-
ble for analysis (figure 1). Gender was approximately
equally distributed (Table 1). Mean age was 38.8 ± 12.6
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51.1%) had a university degree, with significant higher
proportions among the business travellers (p = 0.0057).
Mean travel duration was 3.2 weeks with the most fre-
quently visited destinations being Southeast (SE) Asia
(636, 22.7%), followed by East Africa (522, 18.6%), the
Indian subcontinent (476, 17.0%) and South America
(435,15.5%). The classic TD and all TD incidence rates
for various regions are shown in figure 2 with the high-
est rates reported in most parts of Africa and on the
Indian subcontinent. The largest group of travellers
were tourists (1539; 87.9%), while 121 (10.8%) went for
business; 90 (5.1%) visited friends and relatives (VFR).
The median travel time for business was 2 weeks, while
VFR and tourists travelled for a median duration of
3 weeks. A significantly higher proportion of business-
men visited the Indian subcontinent (44; 15.3%, p <
0.0001) and was male (69; 57.0%, p = 0.0132). Africa
was the preferred continent of tourists (508, 33.1%),
while VFR mainly travelled to Latin America (38; 42.2%)
and Asia (22; 24.4%). A minority visited the tropics or
subtropics for the first time (208, 7.5%), among whom
92 (44.2%) rated themselves as intermediate to very sus-
ceptible to diarrhoea, compared to 940 (36.7%) among
experienced travellers. Post-travel questionnaires were
returned within a median of 10 days (interquartile range
2-30) after returning home.
Among other diseases (596; 25.8%), common cold
(277, 9.9%) and headache (106; 3.8%) were most
reported. Fever independent from TD was mentioned by
45 (2.5%) study participants.
Travellers’ diarrhoea
Among the 2800 exposed, 962 had TD, resulting in a
TD attack rate of 34.4% (95% CI 32.6-36.1) and in a
worldwide TD incidence for the first two-weeks stay of
26.2% (95% CI 24.5-27.8). A majority of 573 volunteers
(69.8%) reported a single TD episode, 248 (30.2%) suf-
fered from more than one episode while abroad. The
number of TD episodes experienced increased approxi-
mately linearly with the duration of stay as illustrated in
figure 3. A total of 785 suffered classic TD while abroad
Figure 1 Overview of prospective participants recruitment.
1) functional gastrointestinal disease.
2) Informed consent
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Page 3 of 9Table 1 Demographic and selected behavioural factors of the travellers’ cohort
Total subgroups
TD
n = 962
mild diarrhoea
n = 303
no diarrhoea abroad
n = 1535
Classic TD
n = 785
Sex n = 2800
Female 1406 (50.2) 466 (33.1) 151 (10.7) 789 (56.1) 400 (28.4)
Male 1394 (49.8) 496 (35.6) 152 (10.9) 746 (53.5) 385 (27.6)
Age group, years
1) n = 2672
18-30 829 (31.0) 338 (40.8) 93 (11.2) 389 (46.9) 292 (35.2)
31-40 882 (33.0) 283 (32.1) 102 (11.6) 497 (56.3) 230 (26.1)
41-60 734 (27.5) 242 (33.0) 76 (10.4) 416 (56.7) 186 (25.3)
>60 227 (8.5) 55 (24.2) 18 (7.9) 154 (67.8) 40 (17.6)
Origin (first 5 years of life) n = 2764
European 2616 (94.6) 899 (34.4) 287 (11.0) 1430 (54.7) 734 (28.0)
TD high risk country
2) 75 (2.7) 25 (33.3) 6 (8.0) 44 (58.7) 19 (25.3)
other 73 (2.6) 24 (32.9) 8 (10.9) 41 (56.2) 19 (26.0)
Education n = 2745
Vocational school level 1
3) 588 (21.4) 196 (33.3) 71 (12.1) 324 (55.1) 151 (25.7)
Vocational school level 2
4) 754 (27.5) 258 (34.2) 75 (9.9) 421 (55.8) 212 (28.1)
University 1403 (51.1) 504 (35.9) 152 (10.8) 758 (54.0) 407 (29.0)
Destination
5) n = 2790
Africa 903 (32.4) 313 (34.7) 107 (11.8) 483 (53.5) 246 (27.2)
Asia 1266 (45.4) 407 (32.1) 126 (10.0) 733 (57.9) 335 (26.5)
Latin America 617 (22.1) 234 (37.9) 70 (11.3) 313 (50.7) 202 (32.7)
Travel type n = 1750
Tourism 1539 (87.9) 545 (35.4) 173 (11.2) 821 (53.3) 444 (28.8)
Family/VFR 90 (5.1) 42 (46.6) 15 (16.6) 33 (36.7) 36 (40.0)
Business 121 (10.8) 37 (30.6) 10 (8.3) 74 (61.2) 27 (22.3)
Travel duration, weeks
1) n = 2800
mean ± sd 3.2 ± 1.6 3.6 ± 1.9 3.2 ± 1.6 3.0 ± 1.4 3.7 ± 1.9
median (range) 3 (1-8) 3 (1-8) 3 (1-8) 3 (1-8) 3 (1-8)
1-3 weeks 1849 (66.0) 560 (30.3) 206 (11.1) 1083 (58.6) 447 (24.2)
3.5 -5 weeks 674 (24.1) 249 (36.9) 74 (11.0) 351 (52.1) 205 (82.3)
5.5-8 weeks 277 (9.9) 153 (55.2) 23 (8.3) 101 (36.5) 133 (48.0)
History of travel n = 2768
Experienced 2560 (92.5) 867 (33.9) 275 (10.7) 1418 (55.4) 706 (27.6)
Newcomer (first such journey) 208 (7.5) 84 (40.4) 24 (11.5) 100 (48.1) 70 (33.6)
Smoking habits
n = 2788
previous smoker 1041 (37.3) 369 (35.4) 100 (9.6) 572 (54.9) 299 (28.7)
previous non-smoker 1747 (62.7) 590 (33.7) 201 (11.5) 956 (54.7) 483 (27.6)
n = 2793
smoker 872 (31.2) 314 (36.0) 81 (9.3) 477 (54.7) 263 (30.2)
non-smoker 1921 (68.8) 644 (33.5) 221 (11.5) 477 (24.8) 519 (27.0)
Daily alcohol consumption n = 2790
yes 594 (21.3) 200 (33.7) 70 (11.8) 324 (54.5) 161 (27.1)
>1 glass daily 90 (15.4) 32 (35.6) 10 (11.1) 48 (53.3) 24 (26.7)
no 2196 (78.7) 757 (34.5) 231 (10.5) 324 (14.7) 620 (28.2)
NOTE. TD is travellers’ diarrhoea, three or more unformed stools with or without additional symptom, classic TD with at least one accompanying symptom, mild
diarrhoea one or two unformed stools per 24 hours. VFR is visiting friends and relatives.
1) Significant. Chi square test, p < 0.05 was considered statistically significant. TD patients were compared to those with no diarrhoea abroad. All other factors not
significant.
2) Defined by Steffen et al. [2,4]
3) Swiss obligatory school to apprenticeship school
4) Swiss Matura (baccalaureat, general qualification for university access) and federal diplomas
5) Oceania was omitted as only 4 travellers had visited this region
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Page 4 of 9(28.0%; 95%CI 26.4-29.7) with a classic TD 2-weeks inci-
dence of 19.9 (18.3-21.4 95%CI). A total of 303 (10.8%)
experienced mild diarrhoea. The most frequent accom-
panying symptoms were tenesmus (56.0% among the
TD patients) and cramps (49.2%). Fever (mean 38.4 ±
0.8°C) or vomiting was reported by approximately 15%
(146 with fever, 136 vomiting), and 166 (17.3%) study
subjects suffered from dysentery. The highest 2 weeks
incidence rates for dysentery were recorded in Central
and in Western Africa, and on the Indian subcontinent
(figure 2). A total of 170 (17.7%) TD patients reported
no accompanying symptom, but experienced a median
of 4 stools per 24 hours (range 3-20).
The number of TD episodes reported had no signifi-
cant influence on the use of antibiotics or probiotics
(p =0 . 2 8 2 ,p = 0.532, respectively). In contrast TD
patients who reported treatment with loperamide
(co-medication with antibiotics excluded) had more TD
episodes (OR 1.45, 95% CI 1.05-2.19, p = 0.0026). TD
occurred on average within 2.1 weeks after arrival (med-
ian 2 days) and patients counted on average 4 stools per
day. One in every nine (111, 11.5%) experienced diar-
rhoea for longer than one week, with 37 (3.8%) indivi-
duals suffering from persistent (≥14 days of TD) and 11
(1.1%) from chronic diarrhoea (≥ 30 days). Roughly two
thirds of patients (614, 63.8%) could pursue their
planned activities, but 102 (10.8%) were confined to bed
or consulted a physician, including 60 with dysentery
(36.1% of all dysenteric patients).
Among treated patients, 343 (57.6%) chose an antimo-
tility agent for self-medication of TD, 137 (23.0%) a pro-
biotic and 51 combined both. A total of 116 (12.3%) TD
patients reported intake of antibiotics, 65 of them
(56.0%) for diarrhoea. The most frequently used antibio-
tics against TD were quinolones (e.g. ciprofloxacin), but
trimethoprim-sulfamethoxazole were also reported
(6 cases). The use of charcoal was reported by 70 per-
sons (19.5%) and oral rehydration treatment was men-
tioned in 62 (6.4%) of the TD subjects and in 16 (9.6%)
Figure 2 First two-week-incidences in selected areas. (N = 2794). CTD classic TD (n = 523). ATD all TD (n = 710). DYS dysentery (n = 166)
Figure 3 Number of TD episodes by weeks of stay within a
high-risk region. (n = 821). High-risk TD regions as defined by
Steffen et al. [2,4]. 1) 1 episode (n = 573). Median 3 (1-8), mean 3.4
± 1.7 weeks. 2) 2 episodes (≥72 h-interval) (n = 189). Median 3.5 (1-
8), mean 4.1 ± 2.0 weeks. 3) 3 episodes (≥72 h-interval) (n = 51).
Median 4 (2-8), mean 4.4 ± 2.0 weeks. 4) 4 episodes (≥72 h-interval)
(n = 8). Median 6 (2-8), mean 5.9 ± 2.0 weeks. Participants with
missing episodes n = 141 (14.7%)
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(21.1%) were treated with an antibiotic, 79 (47.6%) used
non-antibiotic medication exclusively, and this was most
commonly loperamide (n = 38). Against advice, 152
(58.7%; p = 0.0191) travellers with an academic back-
ground reported consumption of tap water, and 60
(39.5%) of those developed TD. Health characteristics
and some preventive attitudes are reported in table 2.
Factors influencing TD
Table 3 shows risk factors independently associated
with TD with increasing age being the only protective
one. We found no significant associations, either with
other reported allergies (e.g. hay fever, atopic dermati-
tis), nor with other pre-travel co-medications (e.g. hor-
monal). Seasonality and gender were not associated to
TD rates.
Table 2 Health characteristics and TD-preventive attitudes abroad (N = 2800)
Total
1) subgroups p value
2)
TD
n = 962
mild diarrhoea
n = 303
no diarrhoea abroad
n = 1535
Body Mass Index n = 2789 0.734
<18.5 91 (3.3) 32 (35.2) 9 (9.9) 50 (54.9)
18.5-29.9 2612 (93.7) 892 (34.2) 283 (10.8) 1437 (55.0)
≥30.0 86 (3.0) 34 (39.5) 9 (10.5) 43 (50.0)
Allergy (MD assessed)
3) n = 2785 0.721
none 1837 (66.0) 627 (34.1) 205 (11.2) 1005 (54.7)
any 632 (34.0) 224 (35.4) 59 (9.3) 349 (55.2)
allergic asthma 110 (17.5) 50 (45.5) 11 (10.0) 49 (44.5)
allergic asthma vs. others 0.013
Comedication
3) n = 2800 0.741
none 2475 (88.4) 853 (34.5) 265 (10.7) 1357 (54.8)
any 325 (11.6) 109 (33.5) 38 (11.7) 178 (54.8)
mental/behavioural
4) 52 (16.8) 25 (23.6) 5 (9.6) 22 (13.3)
mental/behavioural vs. others 0.031
History of diarrhoea n = 1843 n = 674 n = 215 n = 954 0.009
none 855 (46.4) 282 (33.0) 99 (11.6) 474 (55.4)
TD ever experienced 955 (51.8) 377 (39.5) 110 (11.5) 468 (49.0)
Don’t remember 33 (1.8) 15 (45.5) 6 (18.2) 12 (36.4)
History of TD incapacitation n = 1029 n = 373 n = 120 n = 497 0.139
low 528 (51.3) 197 (37.3) 65 (12.3) 266 (50.4)
intermediate to severe 501 (48.7) 215 (42.9) 55 (11.0) 231 (46.1)
Subjective diarrhoea susceptibility n = 1656 n = 584 n = 186 n = 886 0.001
low 617 (37.3) 186 (30.1) 54 (8.7) 377 (61.1)
intermediate 974 (58.8) 363 (37.3) 125 (12.8) 486 (49.9)
high 65 (3.9) 35 (53.8) 7 (10.7) 23 (35.4)
Diarrhoea episode <4 months before index travel
5) n = 2800 <0.001
347 (12.4) 172 (49.6) 42 (13.9) 133 (38.3)
Catering
3) n = 2323 n = 792 n = 252 n = 1279
Buffet meals 2190 (94.3) 742 (33.9) 234 (10.7) 1214 (55.4) 0.380
Private/family meals 982 (42.3) 374 (38.1) 91 (9.3) 517 (52.6) 0.001
Street vendors meals 882 (38.0) 310 (35.1) 98 (11.1) 474 (53.7) 0.389
Adherence to “cook it, boil it, peel it or forget it” n = 2318 0.299
1428 (61.6) 477 (33.4) 160 (11.2) 791 (55.4)
NOTE. P < 0.05 was considered statistically significant. NS, not significant. MD is medical doctor, TD travellers’ diarrhoea.
1) Included mentioned subgroups and mild diarrhoea cases
2) chi square test. TD patients were compared to those with no diarrhoea abroad.
3) Multiple answers possible
4) Mainly antidepressive medication (n = 49)
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In view of the fact that the TD incidence has been
reduced in some countries such as Jamaica [16] and
Thailand [17], updated worldwide regional incidence
data were long overdue. Overall, we observe a substan-
tial decrease in the two weeks incidence rate, nowhere
did we find rates exceeding 50 or even 60% as docu-
mented in a large study conducted a decade ago (3, 4).
Most regions which were high risk remained in high
risk destination group [2,3,8,18,19]. Particularly East
Asia, including China, Southeast Asia and to a lesser
degree Latin America, showed a marked decrease in
classic TD risk. Known high-risk TD destinations such
a st h eM i d d l eE a s t ,N o r t hA f r i c aa n dt h eC a r i b b e a n
have been underrepresented in our study, since visitors
to those destinations generally do not consider a pre-
travel consultation as indicated [20]. Some of these
areas however, recently experienced a similar decrease
in fecal-orally transmitted diseases[21]. For TD we con-
firmed younger age and longer travel duration as risk
factors. In contrast, neither smoking nor consuming
alcohol nor gender significantly influenced the occur-
rence of TD. TD patients, who had previously experi-
enced TD, reported a significantly higher susceptibility
to diarrhoea (p = 0.0127); that may be associated with
genetic factors [22,23].
Allergic asthma, mental/behavioural co-medication, a
high BMI, and a TD-independent fever episode to our
knowledge have so far never been considered risk fac-
tors for TD. Such findings, however, may be clinically
relevant and enhanced preventive measures to protect
travellers vulnerable to multiple health impairments
abroad should be considered. Allergic asthma as a risk
factor needs further exploration [24,25], however both,
atopic dermatitis and hay fever did not influence TD in
our cohort. Within psychiatric co-medication antide-
pressants might be associated with diarrhoea as a side
effect [26,27]. An elevated BMI resulted in a marginally
increased risk ratio, similarly to being a predisposing
factor for community-based diarrhoea [28-30]. Obese
people have a higher food intake, and may thus con-
sume a larger inoculum of pathogens. Lastly, a fever
episode independent of TD was suggestive of some low-
grade inflammatory and/or immunological processes
[31,32]. Our questionnaire did not allow to assess the
chronology of TD independent fever.
Loperamide was widely used to treat TD in our
cohort, which is consistent with other reports [10,33]
and some of the guidelines [34,35]. Only a minority of
6.8% of all cases relied on an antibiotic therapy for TD,
which in most cases was carried in their travel medical
kit. Almost 10% turned to a local pharmacy, potentially
Table 3 Odds ratios (OR) for the risk factors of developing TD
Variable Univariate OR
N = 2800
Multiple OR
N = 2565
Final model OR
N = 2565
Gender
1) 0.90 (0.77-1.05) 1.01 (0.80-1.28) 0.96 (0.80-1.15)
Age (years)
2) 3) 0.98 (0.98-0.99) 0.98 (0.97-1.00) 0.98 (0.98-0.99)
Weeks of stay
3) 1.26 (1.20-1.33) 1.27 (1.17-1.37) 1.28 (1.21-1.35)
Visiting Friends and Relatives
2) 1.62 (1.06-2.48) 1.41 (0.85-2.33)
Smoking
1) 1.11 (0.94-1.32) 1.06 (0.82-1.36)
Daily alcohol drinking
1) 0.94 (0.79-1.17) 1.01 (0.76-1.34)
Allergic asthma
1) 1.62 (1.11-2.38) 1.70 (0.95-3.07) 1.67 (1.10-2.54)
Psychiatric co-medication
1) 1.79 (1.05-3.08) 1.88 (0.94-3.75) 2.11 (1.17-3.80)
Diarrhoea pre-travel
1) 2.07 (1.65-2.59) 1.78 (1.31-2.43) 2.03 (1.59-2.54)
TD independent fever
1) 4) 8.64 (4.01-17.85) 5.72 (2.27-14.38) 6.56 (3.06-14.04)
Malaria chemoprophylaxis
1) 1.19 (0.98-1.44) 1.31 (1.00-1.72) 1.38 (1.12-1.70)
Consuming tap water abroad
1) 1.08 (0.82-1.41) 0.88 (0.62-1.25)
Self-reported adherence to “cook it, boil it, peel it or forget it”
1) 0.91 (0.76-1.09) 1.00 (0.79-1.27)
Body Mass Index
3) 1.01 (0.99-1.04) 1.05 (1.01-1.09) 1.04 (1.01-1.08)
Adverse life event pre-travel
1) 0.94 (0.72-1.22) 0.98 (0.66-1.46)
High stress level pre-travel
1) 1.11 (0.84-1.47) 0.94 (0.62-1.42)
NOTE. OR: Odds ratio
1) Reference group of variable: all others. For Gender Male. For Visiting Friends and Relatives Tourists and Business Travellers, for Smoking Non-smokers (previous
smokers included), for Daily alcohol drinking No daily alcohol drinking reported, for Allergic asthma No allergic asthma reported, for Psychiatric co-medication No
Psychiatric co-medication reported, for Diarrhoea pre-travel No diarrhoea pre-travel, for TD independent fever All others, for Malaria chemoprophylaxis No malaria
chemoprophylaxis reported, for Consuming tap water abroad No such consuming reported, for Self-reported adherence to “cook it, boil it, peel it or forget it“ Self-
reported non-adherence, for Adverse life event No adverse life event reported pre-travel, for High stress level Very low to intermediate stress level pre-travel.
2) Some missing data which accounts for ~10% less of N in the Final model.
3) Continuous variables
4) Imputation of missing data for later inserted question using the pattern of gender, destination continent and education variables.
Pitzurra et al. BMC Infectious Diseases 2010, 10:231
http://www.biomedcentral.com/1471-2334/10/231
Page 7 of 9exposing themselves to the risk of fake medication
abroad or receiving medication stored at inadequately
temperatures [36,37].
Our study design with inherent selection bias [38] and
missing chronology of TD treatment did not allow eva-
luation of the various treatment schedules. However,
patients without antibiotic TD treatment (most using
loperamide) were found to have significantly more TD
episodes; targeted studies are needed to determine
whether loperamide is associated with recurrent TD
episodes.
Half of our study population had a university degree,
travelling mostly as tourists but also for business. They
might spend more money on travelling and be more
likely to ask for pre-travel health advice. Hence, our
results, although not ideal with respect to behaviour,
m a yr e f l e c tar a t h e rh i g hs o c i o - e c o n o m i cs t r a t u m .A s
our study participants all obtained the usual advice on
hygiene measures to prevent TD, and as many were non
compliant these approaches need to be improved, or
other means of prophylaxis offered. For instance, an
alternative approach may be to increase the public and
tourism industry demand for food safety to reduce the
burden of TD among travellers [39]. Previous studies
o f t e nq u e s t i o n e dt r a v e l l e r sa tt h ea i r p o r tb e f o r eo rd u r -
ing the flight home, this one, however, some days after
return. Thus, this latter study would also include TD
which occurred in those first days back home, and one
would expect slightly higher rates as compared to the
older studies.
Conclusion
This study shows that diarrhoea remains a very frequent
health problem in travellers, although there is a trend to
reduced incidence rates in various parts of the world.
Besides well-known risk factors like duration of stay,
young adult age, etc., also a patients’ history of allergic
asthma, of pre-travel diarrhoea and of TD-independent
fever will need further investigation.
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